The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 1971, 106: 781-785.
Copyright © 1971 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaufman, S. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kaufman, S. J.

Selective Inhibition of Cells in the Immune Response by Actinomycin D

Stephen J. Kaufman

From the Department of Microbiology, University of Colorado Medical Center, Denver, Colorado 80220

Abstract

A simple method is described for completely and selectively inhibiting one cell population that is required for in vitro and in vivo antibody responses to sheep erythrocyte antigens. This cell population, which is present in both 7-day immune spleen cells and in bone marrow-derived spleen cells, is completely inhibited by treatment with 0.01 µg/ml actinomycin D for 1 hr. These cells are also relatively resistant to radiation. A second cell type present in immune spleen cells is identified by resistance to this dose of actinomycin D, but is susceptible to a 10-fold higher concentration of the drug.




This article has been cited by other articles:


Home page
ScienceHome page
O. Sharma
Induction of ovalbumin synthesis in immature chicks by actinomycin D and thioacetamide
Science, October 6, 1978; 202(4363): 68 - 69.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1971 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1971 by The American Association of Immunologists, Inc. All rights reserved.